Feature Article: 20 Years After the National Health Insurance Act, HTA Policy Changes Reshape Market Access in South Korea
Market Trends and Updates: New Pharmaceutical Policies Have Dramatically Changed the Landscape in China
Therapeutic Spotlight: New Evidence Brings Cautious Optimism to Alzheimer’s Disease Treatment
Integration of Patient-Reported Outcomes (PROs) and the Patient Voice: A Review of 6 Health Technology Assessment (HTA) Agencies
Changes in Medicare Part D Benefit Design Can Impact Availability of Future Treatments
Xcenda Celebrates 25th Anniversary by Launching New Value & Market Access Solutions
Upending the Medicare Part B Program: The International Pricing Index (IPI) Proposed Model
The Evolving Healthcare Landscape and the Impact on Patient Access and Affordability
Managing the Growing Expansion of Copay Accumulators
Medicare Part B: Do Providers Choose Treatment Based on Payment?
What does Medicare claims data reveal about physician-administered drugs? An Xcenda survey reveals whether physicians choose treatment based on how much they're reimbursed.
Xcenda Collaborated with MAPRx to Publish New Report Addressing Medicare Part D Challenges to Beneficiaries
Responding to Stakeholder Input: Finding the Patient Voice in ICER's Value Assessments
Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?
Emerging Trends in PBM Restrictions on Commercial Copay Assistance
How Policy Impacts Patient Support
What role does the changing healthcare coverage landscape play in support program demand and design?
How to Navigate Cell and Gene Therapy Reimbursement: Part One
An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.
How to Navigate Cell and Gene Therapy Reimbursement: Part Two
An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.
Applying Cost-Effectiveness Thresholds to the Real World: Implications on Access for Medicare Beneficiaries
Payer Tactics to Manage Commercial Copay Assistance Gaining Traction
2018 Trends-Leaning Into the Chaos
What's next in the healthcare environment for 2018? Our Health Policy Weekly editors, Jennifer Snow and Scott Shields, examine key healthcare trends for 2018 in a new issue brief.
Xcenda Collaborates with Family Reach on Critical Issue - Cancer-Related Financial Toxicity
Xcenda Conducts Unique Research on Air Medical Services Costs
The Association of Air Medical Services (AAMS) commissioned Xcenda, part of AmerisourceBergen, to conduct independent research on the costs associated with providing emergent air medical transports. The commissioned study is in response to an evident need for reputable, independent research to quantify the costs associated with providing emergent air medical transports.